Drug Profile
Riluzole sublingual - Biohaven Pharmaceuticals
Alternative Names: BHV-0223; NurtecLatest Information Update: 13 Oct 2022
Price :
$50
*
At a glance
- Originator Yale University
- Developer Biohaven Pharmaceuticals; Yale University
- Class Benzothiazoles; Neuroprotectants; Small molecules
- Mechanism of Action Excitatory amino acid antagonists; Glutamate release inhibitors; Voltage-gated sodium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Amyotrophic lateral sclerosis
- Phase II/III Social phobia
- No development reported Generalised anxiety disorder; Mood disorders